Warfarin Therapy Guidelines

Introduction to Warfarin Therapy

The American College of Cardiology recommends a target therapeutic INR range of 2.0-3.0 for most patients on warfarin, with a baseline INR of 1.0 for patients not on warfarin 1, 2
The American Geriatrics Society notes that the INR is the standardized method of monitoring and reporting the intensity of anticoagulation with warfarin 2
Warfarin's anticoagulant effect is observed within 2 to 7 days after beginning therapy, depending on the dose administered, according to the American College of Cardiology 1

The American College of Cardiology and the American Geriatrics Society recommend an INR range of 2.0-3.0 for most indications, including atrial fibrillation, venous thromboembolism, and rheumatic heart disease 2, 3
For patients with mechanical heart valves, the American Geriatrics Society recommends a higher target INR range of 2.5-3.5 2
The American College of Cardiology recommends an INR range of 2.5-3.5 for patients at extremely high risk of stroke 3

The American College of Cardiology recommends checking INR daily until the therapeutic range is reached and sustained for 2 consecutive days, then 2-3 times weekly for 1-2 weeks, and finally weekly for 1 month 1, 2
Once stable, monitoring can be reduced to intervals as long as 4 weeks, according to the American College of Cardiology and the American Geriatrics Society 1, 2
More frequent monitoring is required during fluctuations in diet, weight changes, medication changes, illness, or any indication of bleeding, as noted by the American Geriatrics Society 2

The American College of Cardiology notes that subtherapeutic anticoagulation (INR <2.0) significantly increases the risk of thromboembolism 1
The risk of bleeding increases exponentially when the INR exceeds the upper limit of the therapeutic range, according to the American College of Cardiology 1, 4
A disproportionate number of thromboembolic and bleeding events occur when the INR is outside the therapeutic range, as reported by the American College of Cardiology 1

The American College of Cardiology recommends that elderly patients (>65 years) may require lower maintenance doses of warfarin due to increased sensitivity 1
Inconsistent vitamin K intake through diet can cause fluctuations in INR values, according to Praxis Medical Insights 5
Targeting lower INR ranges (e.g., 1.5-2.0) without strong evidence may lead to inadequate protection against thromboembolism, as noted by Praxis Medical Insights 5

Atrial fibrillation with stroke risk factors, venous thromboembolism, valvular heart disease, and cardioversion require INR 2.0-3.0, according to the American College of Cardiology 6
Mitral valve disease with prior embolic stroke requires INR 3.0-4.5, as recommended by the American Heart Association 6

For an INR target of 2.5, measurement error should not exceed ±0.5, which represents a relative total expanded error of ±20%, as stated by the International Society on Thrombosis and Haemostasis 7, 8

INR targets below 2.0 lack objective validation and may lead to inadequate protection against thromboembolism, according to the American College of Chest Physicians 6, 9, 10

The risk of bleeding increases exponentially when INR exceeds 4.0, and becomes sharply elevated at INR ≥5.0, according to the American College of Cardiology 11, 12, 13
For patients with INR values between 4-6, intervention is required even without active bleeding, as recommended by the American College of Cardiology 11, 12
High-dose vitamin K (10 mg) for elevated INR may cause warfarin resistance lasting up to one week; the American College of Cardiology suggests using lower doses (1-2.5 mg orally) for INR 4-10 11, 14

For INR 4-5 without bleeding, the American College of Cardiology recommends reducing or omitting the next warfarin dose and resuming at a lower dose when INR approaches the therapeutic range 14
For INR 5-9 without bleeding, omitting 1-2 doses of warfarin or giving oral vitamin K 1-2.5 mg is recommended if the patient has bleeding risk factors, according to the American College of Cardiology 14
For INR >9 without bleeding, the American College of Cardiology suggests giving oral vitamin K 3-5 mg with expected INR reduction within 24-48 hours 14
In cases of serious bleeding or life-threatening overdose, the American College of Cardiology recommends administering vitamin K 10 mg by slow IV infusion over 30 minutes plus fresh frozen plasma or prothrombin complex concentrate 14

Mechanical heart valves (mitral position or older ball‑cage models) require a higher‑intensity anticoagulation target of INR 2.5–3.5 to reduce thromboembolic risk in these high‑risk prostheses. 15 – American Geriatrics Society
Patients with mitral valve disease who have experienced a prior embolic stroke may need an even higher target INR of 3.0–4.5 to provide adequate protection against recurrent embolism. 16

After the therapeutic INR is first achieved and sustained for two consecutive days, INR should be checked 2–3 times per week for the next 1–2 weeks, then weekly for the following month to ensure continued stability. 15 – American Geriatrics Society
When INR has remained stable, monitoring intervals can be safely extended up to 4 weeks (and up to 12 weeks for patients with consistently stable values), reducing the burden of frequent testing. 15 – American Geriatrics Society
More frequent INR checks are mandatory during any of the following situations:
- Initiation or change of medications, especially antibiotics
- Significant dietary changes or weight fluctuations
- Intercurrent illness or fever
- Any clinical indication of bleeding risk
  (All situations supported by the same evidence source.) 15 – American Geriatrics Society

If INR rises to 3.0–5.0 without evidence of bleeding, withhold one warfarin dose or reduce the daily dose, then resume therapy at a lower dose once the INR trends back toward the therapeutic range. 15 – American Geriatrics Society